Mesoblast Limited

Healthcare · Biotechnology · Australia

Last price 15.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.12B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is i...